Skip to content

Effect of Intravenous Hyoscine Butylbromide Injection on First Stage Labour in Primigavidae

Effect of Intravenous Hyoscine Butylbromide Injection on the Course and Duration of First Stage of Labour in Primigavidae

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02824679
Enrollment
200
Registered
2016-07-07
Start date
2015-07-31
Completion date
2017-03-31
Last updated
2021-12-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaginal Delivery

Keywords

Normal labour, Augmentation of labour, Hyoscine butylbromide

Brief summary

A case control study conducted on 120 women coming to Cairo University Maternity Hospital .Patients who meet the inclusion criteria were asked to participate in the study and a verbal consent was obtained from each patient. Patients will be divided into three equal groups (A, B, C). A single dose of the drug (placebo or HBB 20mg or HBB 40 mg) will be injected intravenously slowly to groups A, B, C respectively. Labouring mothers will be monitored in bed. Vaginal examination will be conducted every two hours. The duration of the first stage was calculated from the time of cervical dilatation of three to four centimeters in active labour until a fully dilated cervix will be observed

Detailed description

A case control study conducted on 120 women coming to Cairo University Maternity Hospital .Patients who meet the inclusion criteria were asked to participate in the study and a verbal consent was obtained from each patient. Patients will be divided into three equal groups (A, B, C). A single dose of the drug (placebo or HBB 20mg or HBB 40 mg) will be injected intravenously slowly to groups A, B, C respectively. Labouring mothers will be monitored in bed. Vaginal examination will be conducted every two hours. The duration of the first stage was calculated from the time of cervical dilatation of three to four centimeters in active labour until a fully dilated cervix will be observed

Interventions

20 - 40 mg of hyoscine butylbromide is given intravenously during the first stage of labor

DRUGsaline

0.9%normal saline

Sponsors

Ahmed M Maged, MD
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

1. Age: 18 - 35 years old 2. Primigravdae. 3. Gestational age between completed 37- 41 weeks + 6 days. 4. Uncomplicated cephalic singleton pregnancy occipto-anterior position. 5. Established spontaneous active labour (defined as the presence of at least three regular uterine contractions over 10 minutes with cervical dilatation three to four centimeters) with cervical effacement not less than 50%. 6. Intact amniotic membranes.

Exclusion criteria

1. Multigravidae. 2. Multiple fetus. 3. Malpresentation. 4. Patients with indications of elective caesarean section. 5. Medical conditions associated with pregnancy e.g. preeclampsia, diabetes mellitus. 6. Contraindications for hyoscine butylbromide which include known allergy to hyoscine or other atropinics (e.g., atropine, scopolamine), myasthenia gravis, megacolon or glaucoma. 7. Patients presented to causality with spontaneous rupture of membranes. 8. Spontaneous rupture of membranes during the active phase of first stage of labour. 9. Oxytocin induction or augmentation. 10. Patients who underwent epidural anesthesia or other types of analgesia.

Design outcomes

Primary

MeasureTime frameDescription
first stage duration12 hours after drug intaketime till cervix become fully dilated

Secondary

MeasureTime frameDescription
Mode of delivery12 hours after drug intakeNormal vaginal or cesarean section

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026